Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model
Autor: | Magdalena Klanova, Jan Molinsky, Jan Zivny, Mahmudul Alam, Pavel Klener, Lucie Lateckova, Petra Vockova, Tomáš Soukup, Marek Trneny |
---|---|
Rok vydání: | 2016 |
Předmět: |
Cancer Research
Antimetabolites Antineoplastic medicine.medical_treatment 0206 medical engineering 02 engineering and technology Lymphoma Mantle-Cell Mice SCID CHOP Dexamethasone Mice immune system diseases In vivo Mice Inbred NOD hemic and lymphatic diseases DHAP Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Cyclophosphamide Cell Proliferation Cisplatin Chemotherapy business.industry Cytarabine 021001 nanoscience & nanotechnology medicine.disease 020601 biomedical engineering Xenograft Model Antitumor Assays Lymphoma Disease Models Animal Treatment Outcome Oncology Doxorubicin Vincristine Cancer research Prednisone Mantle cell lymphoma 0210 nano-technology business medicine.drug |
Zdroj: | Neoplasma. 63(5) |
ISSN: | 0028-2685 |
Popis: | Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin lymphoma with adverse prognosis. It was demonstrated that alternation of CHOP and DHAP chemotherapy improved outcome of mantle cell lymphoma patients. However, which components of DHAP, cisplatin, cytarabine, or both, were responsible for the improved outcome remained unclear. To answer this question, antitumor efficacies of equally toxic doses of cytarabine, cisplatin, and three different combinations were compared in vivo using mouse xenograft models of mantle cell lymphoma. We demonstrated that cisplatin, alone or with cytarabine, is significantly superior to single-agent cytarabine in both eliminating lymphoma cells and suppressing their proliferation rate. |
Databáze: | OpenAIRE |
Externí odkaz: |